Metropolis Healthcare Limited has informed the Exchange about Investor Presentation
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare shared its Q2 & H1FY26 investor presentation. For Q2FY26, group revenue grew 23% YoY to INR 429 Cr, EBITDA rose 19% to INR 109 Cr with margin improving to 25.4% (from 23.1% in Q1FY26), and PAT grew 13% to INR 53 Cr. The organic business posted 12% YoY revenue growth with EBITDA margin expanding 210 basis points to 26.8%, driven by operational efficiency and productivity gains. TruHealth and Specialty segments grew 21% and 15% YoY respectively, while recent acquisitions (Core Diagnostics, DAPIC, Scientific Pathology) showed margin improvement from low single-digit to high single-digit. The Board declared a 200% dividend (₹4 per share), and the company reiterated its Metropolis 3.0 strategy targeting mid-teen revenue CAGR through FY26 and pre-Covid margin profile.
Strong double-digit revenue and earnings growth with expanding margins signals solid business momentum and operational leverage. The dividend declaration and reaffirmed multi-year growth targets are likely to be viewed positively by investors.